GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Institutional Ownership

Benevolent AI (Benevolent AI) Institutional Ownership : 1.27% (As of Jun. 10, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Benevolent AI's institutional ownership is 1.27%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Benevolent AI's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Benevolent AI's Float Percentage Of Total Shares Outstanding is 0.00%.


Benevolent AI Institutional Ownership Historical Data

The historical data trend for Benevolent AI's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Institutional Ownership Chart

Benevolent AI Historical Data

The historical data trend for Benevolent AI can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 1.96 1.90 1.83 1.69 1.60 1.57 1.36 1.30 1.27 1.27

Benevolent AI Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Benevolent AI (Benevolent AI) Business Description

Comparable Companies
Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.